Cresset Asset Management’s CorMedix CRMD Stock Holding History

Cresset Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-329,796	Closed	-$1.31M	–	828
2022 Q4	$1.31M	Hold	329,796	–	–	0.02%	262
2022 Q3	$933K	Hold	329,796	–	–	0.01%	372
2022 Q2	$1.33M	Hold	329,796	–	–	0.02%	308
2022 Q1	$1.81M	Hold	329,796	–	–	0.02%	265
2021 Q4	$1.5M	Hold	329,796	–	–	0.01%	349
2021 Q3	$1.53M	Hold	329,796	–	–	0.02%	284
2021 Q2	$2.26M	Hold	329,796	–	–	0.03%	187
2021 Q1	$3.29M	Hold	329,796	–	–	0.05%	127
2020 Q4	$2.45M	Hold	329,796	–	–	0.04%	136
2020 Q3	$1.99M	Hold	329,796	–	–	0.04%	165
2020 Q2	$2.08M	Hold	329,796	–	–	0.05%	144
2020 Q1	$1.18M	Hold	329,796	–	–	0.04%	169
2019 Q4	$2.4M	Hold	329,796	–	–	0.07%	124
2019 Q3	$2.1M	Hold	329,796	–	–	0.06%	129
2019 Q2	$2.96M	Buy	+329,796	New	+$2.59M	0.09%	96
2019 Q1	–	Sell	-329,795	Closed	-$2.13M	–	2005
2018 Q4	$2.13M	Buy	+329,795	New	+$2.21M	0.13%	39

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Cresset Asset Management's CRMD Position: Q1 2023 in Review

Cresset Asset Management sold out of CorMedix (CRMD) in Q1 2023, closing a stake of 329,796 shares — an estimated $1.31M sold.

Cresset Asset Management first reported a position in CRMD in Q4 2018 and held it in 16 quarters. The position peaked at $3.29M in Q1 2021. 65 funds tracked by Wall St. Rank hold CRMD as of Q1 2023.

Cresset Asset Management reported no remaining CorMedix position as of Q1 2023 after selling out during the quarter.
Cresset Asset Management sold 329,796 CorMedix shares in Q1 2023, an estimated $1.31M.
Cresset Asset Management first reported a position in CorMedix in Q4 2018 and held it in 16 quarters.
Cresset Asset Management's CorMedix position peaked at $3.29M in Q1 2021.
65 funds tracked by Wall St. Rank held CorMedix as of Q1 2023.

Based on Cresset Asset Management's 13F filing for Q1 2023, filed 12 May 2023.